|Bid||134.00 x 300|
|Ask||142.00 x 200|
|Day's Range||133.73 - 138.45|
|52 Week Range||75.52 - 153.15|
|PE Ratio (TTM)||-245.60|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Which is the better growth stock going forward -- Exelixis or Incyte? It depends.
Despite rampant rumors, Gilead is not likely to acquire either Incyte or Vertex. Here's why.
Gilead could fill a hole in its portfolio by acquiring Incyte, an analyst suggested Friday, offering one caveat — Vertex would still be a less risky bet.